Drug intelligence / Profile preview

haloperidol + lorazepam

Development stage
Phase 3
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Intramuscular, Intravenous, Oral
01

Overview

Haloperidol + lorazepam is a combination of two pharmaceutical agents used primarily for the rapid tranquilization and management of acute agitation, particularly in psychiatric emergencies. Haloperidol is a high-potency first-generation (typical) antipsychotic that acts mainly as an antagonist at dopamine D2 receptors, reducing psychotic symptoms and agitation. Lorazepam is a short-acting benzodiazepine that acts as a positive allosteric modulator at the GABA(A) receptor, producing sedative, anxiolytic, muscle relaxant, and anticonvulsant effects. The combination is often used when monotherapy with either agent alone does not provide sufficient control of severe agitation or delirium. Clinical studies suggest that while the combination can be effective for controlling acute agitation or persistent delirium (such as in end-of-life care), it may not always offer significant advantages over haloperidol alone in terms of efficacy but may increase risks such as sedation or hypotension[1][2][3][4][9].

02

Targets

DRD2 (Dopamine D2 Receptor)GABAA (Gamma-aminobutyric acid receptor)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on haloperidol + lorazepam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haloperidol + lorazepam.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call